Loading…
NLRP3 inflammasome in depression: A review
•The NLRP3 Inflammasome activation causes the development of different chronic diseases.•Novel drugs for the treatment of depression by inhibiting NLRP3 inflammasome activation.•Several pathways that activate the NLRP3 inflammasome in depression.•Correlation between NLRP3 and depression.•Diagnostic...
Saved in:
Published in: | International immunopharmacology 2023-04, Vol.117, p.109916-109916, Article 109916 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | •The NLRP3 Inflammasome activation causes the development of different chronic diseases.•Novel drugs for the treatment of depression by inhibiting NLRP3 inflammasome activation.•Several pathways that activate the NLRP3 inflammasome in depression.•Correlation between NLRP3 and depression.•Diagnostic marker for NLRP3 induced depression.
The present article provides a detailed concept of the role of NLRP3 inflammasome in the pathophysiology of depression-like chronic diseases where inflammation and release of various cytokines plays a pivotal role in exaggerating the condition. The various pathways involved in NLRP3 activation are the main target of NLRP3 inhibitors for the therapeutic management of depression as per the recent clinical and research studies conducted so far. Further various drug inhibitors for NLRP3 available in preclinical and clinical trials have been discussed in detail. Hence, blockage of the action of NLRP3 inflammasome is crucial to anticipate the inflammatory cytokine release from the mediators that contributes to cause depression. |
---|---|
ISSN: | 1567-5769 1878-1705 |
DOI: | 10.1016/j.intimp.2023.109916 |